Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis, Charles F
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Sep 2004 - 6101-10 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
1078-0432
10.1158/1078-0432.CCR-04-0525 doi
Adult
Aged
Aged, 80 and over
Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents--administration & dosage
Combined Modality Therapy--methods
Female
Humans
Immunotherapy--methods
Interleukin-2--administration & dosage
Killer Cells, Natural--immunology
Leukocytes--immunology
Leukocytes, Mononuclear--metabolism
Lymphoma, B-Cell--immunology
Lymphoma, Non-Hodgkin--immunology
Male
Mice
Mice, SCID
Middle Aged
Rituximab
Time Factors
Treatment Outcome
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Sep 2004 - 6101-10 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
1078-0432
10.1158/1078-0432.CCR-04-0525 doi
Adult
Aged
Aged, 80 and over
Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents--administration & dosage
Combined Modality Therapy--methods
Female
Humans
Immunotherapy--methods
Interleukin-2--administration & dosage
Killer Cells, Natural--immunology
Leukocytes--immunology
Leukocytes, Mononuclear--metabolism
Lymphoma, B-Cell--immunology
Lymphoma, Non-Hodgkin--immunology
Male
Mice
Mice, SCID
Middle Aged
Rituximab
Time Factors
Treatment Outcome